Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
As part of the PREA(Pediatric Research Equity Act) commitment, the objective of the study is
to confirm safety and tolerability of 25 mg of Zipsor® in clinical pediatric subjects.